ライフサイエンスコーパス: cognitive decline

1 decreases local recurrence, but might cause cognitive decline.

2 omography (PET), and their associations with cognitive decline.

3 compared with placebo for the prevention of cognitive decline.

4 ted symptoms in Parkinson disease, including cognitive decline.

5 cal monitoring, can also lead to accelerated cognitive decline.

6 in and associates with immune activation and cognitive decline.

7 ional excitation-transcription coupling, and cognitive decline.

8 suggest that it does not affect the rate of cognitive decline.

9 orm of dementia characterized by progressive cognitive decline.

10 related to risk for later Alzheimer-related cognitive decline.

11 the spreading of tau pathology and possibly cognitive decline.

12 e potential to protect against age-dependent cognitive decline.

13 rative disorder characterized by progressive cognitive decline.

14 Chuan and Baduanjin exercises in preventing cognitive decline.

15 e imaging transverse relaxation in late-life cognitive decline.

16 l haemorrhage and contributor to age-related cognitive decline.

17 dysfunctions, such as Alzheimer's disease or cognitive decline.

18 protects carriers against AD and age-related cognitive decline.

19 Delirium is associated with accelerated cognitive decline.

20 cular risk factors have been associated with cognitive decline.

21 ty and, potentially neuronal dysfunction and cognitive decline.

22 cohol use; and APOE epsilon4 on the rates of cognitive decline.

23 ndrial abnormalities are well known to cause cognitive decline.

24 lso been shown to be potentially involved in cognitive decline.

25 that spans years to decades before onset of cognitive decline.

26 therapeutic strategies aimed at ameliorating cognitive decline.

27 Abeta phagocytosis and the stabilization of cognitive decline.

28 ation, and brain apoptosis, resulting in the cognitive decline.

29 w-up time of at least 2 years and no further cognitive decline.

30 ea for a variety of disorders that result in cognitive decline.

31 with Alzheimer's disease (AD) and can hasten cognitive decline.

32 ase in which patients experience progressive cognitive decline.

33 3) the two act synergistically to accelerate cognitive decline.

34 MCI and dementia; global and domain-specific cognitive decline.

35 sarthria, dystonia, vertical gaze palsy, and cognitive decline.

36 rely and at risk for substantial medical and cognitive decline.

37 ase symptoms such as behavioral disorder and cognitive decline.

38 der adults, and can be used to fight against cognitive decline.

39 e of AD, thereby potentially contributing to cognitive decline.

40 s in longitudinal studies of determinants of cognitive decline.

41 ment disorders, psychiatric disturbances and cognitive decline.

42 in Alzheimer's disease (AD) correlates with cognitive decline.

43 of amyloid-independent tau deposition and/or cognitive decline.

44 ical aging and associated with a more-severe cognitive decline.

45 iduals who have greater likelihood of future cognitive decline.

46 sociated with increased risk of dementia and cognitive decline.

47 tients with early AD that is associated with cognitive decline.

48 national differences in rates of age-related cognitive decline.

49 loid-beta or lacunes have greatest impact on cognitive decline.

50 aracterized by progressive neuronal loss and cognitive decline.

51 o evaluate the effects of imaging markers on cognitive decline.

52 as a potential therapy to treat age-related cognitive decline.

53 s, critically modulating the early stages of cognitive decline.

54 in and associates with immune activation and cognitive decline.

55 y outcome) and secondarily for postoperative cognitive decline.

56 ein, and behavioral deficits associated with cognitive decline.

57 tifactorial drivers of hippocampal aging and cognitive decline.

58 orders and age-related neurodegenerative and cognitive decline.

59 at these supplements did not reduce risk for cognitive decline.

60 or in combination, compared with placebo, on cognitive decline.

61 t on amyloid pathogenesis and the consequent cognitive decline.

62 cations for their respective links to future cognitive decline.

63 tributing to neurodegenerative processes and cognitive decline.

64 ctivation to subsequent Abeta deposition and cognitive decline.

65 s the adverse effects of natural disaster on cognitive decline.

66 tissue properties associated with late-life cognitive decline above and beyond the influence of comm

67 Elderly individuals are at increased risk of cognitive decline after anesthesia.

68 elaxation rate (R2) that was associated with cognitive decline after controlling for common neuropath

69 n, and tobacco and alcohol use had a steeper cognitive decline after onset.

70 increase of approximately 36% in the rate of cognitive decline after the change point when compared w

71 el, was associated with higher likelihood of cognitive decline, although the findings are of uncertai

72 and quantify the risk for Alzheimer-related cognitive decline among cognitively normal individuals w

73 and risk of incident AD in the predictors of cognitive decline among normal individuals (BIOCARD) coh

74 ed effect size is consistent with studies of cognitive decline among offspring of known consanguineou

75 l mechanisms accounting for early vs delayed cognitive decline among patients who have experienced IC

76 se and heart failure may contribute to early cognitive decline and (vascular) dementia.

77 D (mean [SD] age, 70.0 [9.9] at the onset of cognitive decline and 79.2 [9.8] years at death; 509 mal

78 Yet, the relationship of PNS function to cognitive decline and abnormal frontal function that cha

79 ery to reduce the risk of anesthesia-induced cognitive decline and AD.

80 hypoperfusion is associated with accelerated cognitive decline and an increased risk of dementia in t

81 beta (Abeta), potentially triggering earlier cognitive decline and conversion to AD.

82 and network connectivity, which may prevent cognitive decline and could boost the efficacy of extinc

83 f physical activity interventions in slowing cognitive decline and delaying the onset of cognitive im

84 Cognitive reserve (CR) prevents cognitive decline and delays neurodegeneration.

85 sease as a contributory mechanism in causing cognitive decline and dementia and potentially may provi

86 a total tau level as a prognostic marker for cognitive decline and dementia is not well understood.

87 ve impairment, but whether OH contributes to cognitive decline and dementia is uncertain.

88 The association of microbleeds with cognitive decline and dementia was studied using multipl

89 re, surgery may accelerate the trajectory of cognitive decline and dementia.

90 athological events, which ultimately lead to cognitive decline and dementia.

91 fe and offer potential to reduce the risk of cognitive decline and dementia.

92 ostic and prognostic purposes in people with cognitive decline and dementia.

93 may guide development of novel therapies for cognitive decline and dementia.

94 population ages, the burden of disease from cognitive decline and dementing illness is rising.

95 social isolation, loneliness, and consequent cognitive decline and depression.

96 iation of cerebral perfusion with subsequent cognitive decline and development of dementia.

97 ncluding: 300-400% increased risk of stroke, cognitive decline and diminished cerebral blood flow reg

98 g of elderly individuals are associated with cognitive decline and disability.

99 st a clear link between Nrf2 and AD-mediated cognitive decline and further strengthen the connection

100 e epilepsy, which contributes to accelerated cognitive decline and has diagnostic and treatment impli

101 ecific types of GBA mutations and aggressive cognitive decline and have direct implications for impro

102 of exposure and an unmeasured determinant of cognitive decline and in similar settings.

103 Aging is associated with cognitive decline and increasing risk of neurodegenerati

104 d type 2 diabetes are major risk factors for cognitive decline and late onset Alzheimer's disease (AD

105 ressive white matter hyperintensities (WMH), cognitive decline and loss of functional independence.

106 Slower cognitive decline and lower rates of progression to Alzh

107 rietal metabolism is associated with risk of cognitive decline and may represent a potential biomarke

108 t of novel therapeutics aimed to resolve the cognitive decline and memory impairment in AD using DBS

109 yperexcitability are at risk for accelerated cognitive decline and might benefit from antiepileptic t

110 yel) mice exhibit exaggerated progression of cognitive decline and neuroinflammation on an Alzheimer'

111 Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairm

112 baseline B vitamin status, show a slowing of cognitive decline and of atrophy in critical brain regio

113 out psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes.

114 in the disease course have greater rates of cognitive decline and progression to dementia.

115 vel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.

116 function in nondemented PD patients precedes cognitive decline and the development of PDD by several

117 used to investigate the association between cognitive decline and visual field variability, adjustin

118 Association between cognitive decline and visual field variability.

119 ial support were associated with age-related cognitive decline and whether these associations varied

120 rovascular resistance and amyloid retention, cognitive decline, and brain atrophy, controlling for ne

121 he hippocampus, which can lead to sclerosis, cognitive decline, and death.

122 economic marker) with cognitive performance, cognitive decline, and dementia (N dementia/total = 195/

123 isease (AD) is characterized by memory loss, cognitive decline, and devastating neurodegeneration, no

124 synergistically with amyloidosis to produce cognitive decline, and drives amyloid-independent brain

125 iated with cognitive decrements, accelerated cognitive decline, and increased risk for dementia.

126 s, in turn contributing to cerebral atrophy, cognitive decline, and increased risk for psychiatric di

127 ssion of the established MRI markers of SVD, cognitive decline, and increased risk of dementia.

128 l for individualised learning, prevention of cognitive decline, and rehabilitation.

129 association between plasma total tau level, cognitive decline, and risk of mild cognitive impairment

130 Because significant memory loss and cognitive decline are associated with neuron death and l

131 e that the loss of cholinergic signaling and cognitive decline are inextricably linked.

132 strong genetic risk factor for aging-related cognitive decline as well as late-onset Alzheimer's dise

133 ated with olfactory dysregulation, including cognitive decline, as well as monitoring effects of neur

134 mory, yet the role of this metabolism in the cognitive decline associated with Alzheimer's disease (A

135 the brain are believed to contribute to the cognitive decline associated with Alzheimer's disease (A

136 logical and psychiatric disorders, including cognitive decline associated with Alzheimer's disease or

137 ction of cholinergic circuits contributes to cognitive decline associated with neurodegenerative diso

138 ntifying individuals potentially at risk for cognitive decline associated with preclinical AD.SIGNIFI

139 ovided the earliest indicator of preclinical cognitive decline at 32 years of age, 12 and 17 years be

140 Cognitive decline attributable to delirium was -0.37 MMS

141 amined whether retrospective trajectories of cognitive decline (backward timescale) over 18 years pri

142 lobal cognition was characterized by gradual cognitive decline beginning approximately 15 years befor

143 re were no significant differences in 3-year cognitive decline between any of the three intervention

144 s of dementia is associated with accelerated cognitive decline beyond that expected for delirium or t

145 Lower BP targets did not increase falls or cognitive decline but are associated with hypotension, s

146 up level, individuals with SNAP did not show cognitive decline but did show a diminished practice eff

147 cess risk was unchanged after adjustment for cognitive decline but was completely attenuated after ad

148 E 4) allele are risk factors for age-related cognitive decline, but how these risks are modified by h

149 o explain individual differences in rates of cognitive decline, but its potential role as a mediating

150 plasma total tau levels are associated with cognitive decline, but the results differ based on cogni

151 uremic toxin clearance, also contributes to cognitive decline by causing rapid fluid and osmotic shi

152 s undergoing lesion resection: postoperative cognitive decline can be tracked and even predicted usin

153 tion of the effect of an exposure on rate of cognitive decline can occur when mortality is a common e

154 Cognitive decline (CD) was determined by changes in mean

155 A man in his late 40s presented with cognitive decline characterized by gradually increasing

156 ntile cutoff value) in controls and rates of cognitive decline (Clinical Dementia Rating sum of boxes

157 The stage 2 group demonstrated greater cognitive decline compared with all other groups (stage

158 allogeneic HCT recipients showed significant cognitive decline compared with healthy controls.

159 ite matter hyperintensities detected on MRI; cognitive decline defined as composite score changes bet

160 oreover, effective treatments for apathy and cognitive decline do not currently exist.

161 isk of cardiovascular morbidity, accelerated cognitive decline during aging, and Alzheimer's disease

162 APOE2 is associated with less cognitive decline during aging.

163 y, the APOE2 allele was associated with less cognitive decline during aging.

164 Predicting who is at risk of cognitive decline early in the disease course has implic

165 s as low as 3 mg/kg, significantly prevented cognitive decline evaluated by Y-maze spontaneous altern

166 erse relaxation is associated with late-life cognitive decline even after controlling for common neur

167 time to AD dementia and steeper longitudinal cognitive decline, even after controlling for APOE varep

168 ios, assuming that exposure had no effect on cognitive decline for anyone in the population.

169 a spouse/partner was associated with slower cognitive decline (for executive function, betaperson-me

170 sociation with downward mobility mediated by cognitive decline from childhood.

171 tions with midlife cognitive performance and cognitive decline from midlife to old age, including cog

172 with mild cognitive impairment or subjective cognitive decline from the Swedish BioFINDER (Biomarkers

173 ween the DR15 haplotype and greater rates of cognitive decline (greater impairment on the 11-item Alz

174 cation use, hospital records, or significant cognitive decline (>/=1.5 SD race-specific decline on th

175 Age-related cognitive decline has many contributors, and these findi

176 Patients with subjective cognitive decline have been identified as a useful popul

177 ded on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; m

178 ith Alzheimer's disease, seizures can hasten cognitive decline, highlighting the clinical relevance o

179 ippocampal synaptic plasticity and transient cognitive decline, however, the underlying mechanisms re

180 rriers [87.5%]) from the Israel Diabetes and Cognitive Decline (IDCD) study, who had a mean (SD) numb

181 s related to psychiatric disorders including cognitive decline, impaired synaptic plasticity, reduced

182 ions before the onset of plaque formation or cognitive decline in a mouse model of Alzheimer's diseas

183 thogenic tau causes synaptic dysfunction and cognitive decline in AD pathogenesis.

184 ional brain connectivity with progression of cognitive decline in AD.

185 umulation is thought to be closely linked to cognitive decline in AD.

186 rphosphorylation, and synaptic loss underlie cognitive decline in AD.

187 processing, a factor that may contribute to cognitive decline in AD.

188 rcise can convey a protective effect against cognitive decline in ageing and Alzheimer's disease.

189 eline were associated with a greater rate of cognitive decline in all domains (0.04 to 0.09 z score u

190 rative diseases and correlates strongly with cognitive decline in Alzheimer's disease (AD).

191 ng amyloid-beta-induced loss of synapses and cognitive decline in Alzheimer's disease mice.

192 rations in neural function and ultimately to cognitive decline in Alzheimer's disease.

193 sing target for the treatment of later stage cognitive decline in Alzheimer's disease.

194 4 genotype are independent risk factors for cognitive decline in ART-adherent HIV(+) men aged >50 ye

195 l support were independently associated with cognitive decline in different ways according to sex and

196 This study suggests that cognitive decline in dogs is related to the tau synaptic

197 between sleep-disordered breathing (SDB) and cognitive decline in elderly persons.

198 N = 372) to test whether E4 protects against cognitive decline in environments with a heavy pathogen

199 rce of dietary cholesterol, with the risk of cognitive decline in general populations or in carriers

200 Therefore, synapse loss, the hallmark of cognitive decline in HAND, is reversible.

201 sease (GD) in homozygotes lead to aggressive cognitive decline in heterozygous Parkinson's disease (P

202 Synaptodendritic damage correlates with cognitive decline in HIV-associated neurocognitive disor

203 MENT Synaptodendritic damage correlates with cognitive decline in HIV-associated neurocognitive disor

204 version to MCI or AD (p = 0.038) and against cognitive decline in individuals who develop dementia (p

205 the strongest risk factor to date of AD and cognitive decline in industrial populations; it is assoc

206 stage of AD reduces brain atrophy, prevents cognitive decline in LMCI and delays conversion to AD de

207 These findings suggest that VNS attenuates cognitive decline in obese-insulin resistant rats by att

208 ion and biomarkers as predictive factors for cognitive decline in patients with newly diagnosed Parki

209 onal and longitudinal observational study of cognitive decline in patients with symptomatic AD and co

210 ic GD and complex alleles shift longitudinal cognitive decline in PD into "high gear." These findings

211 avor alleles protecting specifically against cognitive decline in postreproductive humans.

212 ding protein, MECP2, the molecular basis for cognitive decline in Rett syndrome and some cases of aut

213 There was no evidence of faster cognitive decline in socioeconomically disadvantaged gro

214 sphorylated tau pathology is associated with cognitive decline in temporal lobe epilepsy and explored

215 ing (CDR) and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); neuropsychiat

216 rs prior to dementia diagnosis showed faster cognitive decline in the high education (p = 0.006) and

217 ive aggregates as tracking most closely with cognitive decline in this model.

218 However, cognitive decline in this population was much lower than

219 of synapses, defective axonal transport and cognitive decline, in patients with AD.

220 ng exercises-are promoted to slow or prevent cognitive decline, including dementia, but their effecti

221 on disorder in aging that is associated with cognitive decline, including significant executive dysfu

222 disease (AD) is characterized by progressive cognitive decline, increasingly attributed to neuronal d

223 mortality or when both exposure and rate of cognitive decline influenced mortality.

224 en exposure and an unmeasured determinant of cognitive decline interacted on the hazard ratio scale t

225 Cognitive decline is a debilitating condition associated

226 Cognitive decline is a debilitating manifestation of dis

227 Subjective cognitive decline is indicative of accumulation of early

228 As cognitive decline is often preceded by significant metab

229 These clinical findings suggest that cognitive decline is the result of a complex pathophysio

230 h tau alters synapse physiology and leads to cognitive decline is unclear.

231 e (AD), but the mechanism by which it causes cognitive decline is unclear.

232 y (SRS), yet because of its association with cognitive decline, its role in the treatment of patients

233 A multidomain intervention showed a delay in cognitive decline (low-strength evidence).

234 er's disease is characterized by progressive cognitive decline, mainly attributed to synaptotoxicity

235 ounter (OTC) supplements to prevent or delay cognitive decline, MCI, or clinical Alzheimer-type demen

236 rmacologic interventions to prevent or delay cognitive decline, MCI, or dementia in adults with norma

237 Cognitive decline measured by a decrease in neuropsychol

238 cohorts, suggesting that different rates of cognitive decline might contribute to the global variati

239 Optimal interventions to prevent or delay cognitive decline, mild cognitive impairment (MCI), or d

240 Optimal treatment to prevent or delay cognitive decline, mild cognitive impairment (MCI), or d

241 aging, these alterations are associated with cognitive decline, neurobehavioral deficits, and increas

242 To examine whether the accelerated cognitive decline observed after delirium is independent

243 ies, we propose that the previously reported cognitive decline observed at 72 h postsurgery in mice m

244 Mild cognitive decline occurred in half.

245 meric amyloid-beta (Abeta) may contribute to cognitive decline of Alzheimer disease, defining the mos

246 ntal sequelae in children with CHD evolve to cognitive decline or dementia during adulthood, a growin

247 tions promote cognitive function and prevent cognitive decline or dementia in older adults is largely

248 Evidence regarding prevention or delay of cognitive decline or dementia is insufficient.

249 peutic options to treat or delay progressive cognitive decline or dementia is very scarce.

250 Evidence for prevention of cognitive decline or dementia was insufficient.

251 ions are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evid

252 Cognitive decline over 2-year follow-up was accelerated

253 n combination, had no significant effects on cognitive decline over 3 years in elderly people with me

254 n at baseline is associated with the rate of cognitive decline over 4 years and potentially provides

255 Higher baseline SUVR projected greater cognitive decline over 4 years.

256 er plasma total tau level is associated with cognitive decline over a short interval of 15 months.

257 aluable information about the rate of future cognitive decline over the subsequent 4 years compared w

258 group would be expected to show the greatest cognitive decline over time if untreated.

259 d LDL-C were associated with faster rates of cognitive decline (P < .01), whereas higher HDL-C attenu

260 1 x 10(-9)), schizophrenia (P=1.6 x 10(-9)), cognitive decline (P=5.3 x 10(-4)) and Parkinson's disea

261 In the absence of treatments to reverse cognitive decline, prevention is a public health priorit

262 s parallel the progressive motor, memory and cognitive decline previously reported as HD monkeys aged

263 FDG metabolism were predictive of subsequent cognitive decline rated with the MMSE and MoCA.

264 ive cognitive dysfunction and other forms of cognitive decline related to immune-to-brain communicati

265 g the MCI stage may contribute to the faster cognitive decline reported in APOE4 carriers.

266 Alzheimer's disease (AD) and age-related cognitive decline represent a growing health burden and

267 nd social participation buffered the risk of cognitive decline resulting from housing damage.

268 mpairment (MCI) and subjects with subjective cognitive decline (SCD) after using the W score method t

269 e associations between reports of subjective cognitive decline (SCD) and biomarkers of early Alzheime

270 R study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI)

271 less favourable prognosis, with accelerated cognitive decline, shorter lifespan, and increased admis

272 Public health steps to slow cognitive decline should be promoted in individuals who

273 lded fewer significant effects of amyloid on cognitive decline than continuous SUVR.

274 portant information about the rate of future cognitive decline that is not available from a dichotomo

275 pid and severe disease progression and early cognitive decline; the pathological features were striki

276 ts, the increased risk of adverse events and cognitive decline, there is an unmet need for well-toler

277 e decline from midlife to old age, including cognitive decline trajectories in those with dementia.

278 tions between social support and age-related cognitive decline vary across different relationship typ

279 expectancy, impaired functional status, and cognitive decline warrant consideration as part of the m

280 impairment, and 40 controls with subjective cognitive decline was analyzed using multiplex isobaric

281 Cognitive decline was associated with increased visual f

282 The association of R2 with cognitive decline was attenuated when the gene expressio

283 Their cognitive decline was decreased compared with controls,

284 Onset of cognitive decline was delayed by 3 years in individuals

285 Preclinical cognitive decline was evident in PSEN1 E280A mutation ca

286 Subjective cognitive decline was measured using a previously publis

287 onse relationship between amyloid burden and cognitive decline was present among middle-aged and olde

288 Cognitive decline was then analysed between clusters usi

289 women at varying stages of brain atrophy and cognitive decline, we found that intra-item configural p

290 older adult humans at the earliest stages of cognitive decline, we show here that alERC volume select

291 progression, development of dyskinesias, and cognitive decline were observed.

292 d/or B12 tested as protective agents against cognitive decline were poorly designed by including subj

293 Candidate predictors of cognitive decline were selected through a backward elimi

294 saccades, dysphagia, apathy, and progressive cognitive decline, which led to her death 2 years later.

295 reviously documented effect of depression on cognitive decline, while UNC5C may alter the composition

296 spectively, elevated tHcy is associated with cognitive decline, white matter damage, brain atrophy, n

297 nt, carriers had a statistically significant cognitive decline with a loss of 0.24 (95% CI, -0.26 to

298 ollowing year, the patient experienced rapid cognitive decline with new-onset recurrent visual halluc

299 nt were evaluated for AD and other causes of cognitive decline, with a prescan diagnostic confidence

300 l sclerosis were associated with progressive cognitive decline, with their deleterious effects increa